Some patients with TED need longer to respond to teprotumumab
Patients with thyroid eye disease (TED) treated with teprotumumab may need longer than 12 weeks to see a clinically significant response, according to a study. Approximately half of the patients treated with teprotumumab experience significant improvements in proptosis at 6 weeks, according to recent trials, with a small subgroup not...
Read MoreVideos
Contact Info
© 2024 Ophthalmology 360® is a trademark of International Healthcare Media, LLC. All rights Reserved